AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
Summary
Insilico Medicine announced the nomination of ISM9077 as a preclinical candidate for ocular diseases, inflammatory disorders, and aging-related conditions. The company says its generative AI platform helped design and optimize the molecule, which shows strong preclinical efficacy, good permeability, and a favorable safety profile. The candidate targets dry AMD, uveitis, and dry eye disease, and it may support both oral and eye drop delivery. Insilico also positions the program as evidence that its AI-driven discovery process can produce candidates at scale.
Classifications
industries
No industries detected
applications
Data Management
AskAI Classifications
Labels
SaaS
AI/ML Platforms
Bioinformatics Software
Linked Companies
Insilico Medicine
$25M to $50M